Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Priorities for developing respiratory syncytial virus vaccines in different target populations.

Drysdale, SB; Barr, RS; Rollier, CS; Green, CA; Pollard, AJ; Sande, CJ (2020) Priorities for developing respiratory syncytial virus vaccines in different target populations. Sci Transl Med, 12 (535). eaax2466. ISSN 1946-6242
SGUL Authors: Drysdale, Simon Bruce

[img] Microsoft Word (.docx) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (218kB)


The development of an effective vaccine against respiratory syncytial virus (RSV) has been hampered by major difficulties that occurred in the 1960s when a formalin-inactivated vaccine led to increased severity of RSV disease after acquisition of the virus in the RSV season after vaccination. Recent renewed efforts to develop a vaccine have resulted in about 38 candidate vaccines and monoclonal antibodies now in clinical development. The target populations for effective vaccination are varied and include neonates, young children, pregnant women, and older adults. The reasons for susceptibility to infection in each of these groups may be different and, therefore, could require different vaccine types for induction of protective immune responses, adding a further challenge for vaccine development. Here, we review the current knowledge of RSV vaccine development for these target populations and propose a view and rationale for prioritizing RSV vaccine development.

Item Type: Article
Additional Information: Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Keywords: 11 Medical and Health Sciences, 06 Biological Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Sci Transl Med
ISSN: 1946-6242
Language: eng
18 March 2020Published
25 September 2019Accepted
Publisher License: Publisher's own licence
Project IDFunderFunder ID
UNSPECIFIEDNational Institute for Health Research
116019Innovative Medicines InitiativeUNSPECIFIED
WT105882MAWellcome Trust
PubMed ID: 32188721
Go to PubMed abstract
Publisher's version:

Actions (login required)

Edit Item Edit Item